Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets

Pharmaceutical shares drew renewed attention as investors rotated away from technology names, with AbbVie, Eli Lilly and Gilead Sciences closing near record levels. The move reflects a familiar pattern: when volatility rises in one part of the market, capital often migrates toward sectors perceived as more defensive.

Large-cap drugmakers tend to fit that description because demand for medicines is less tied to the economic cycle than spending on discretionary goods or advertising. Many of these companies also carry durable revenue streams from established treatments and pipelines, which can make their cash flows easier to model during uncertain periods.

What to watch from here is whether the shift proves lasting or simply a short-term rotation. Sector performance will continue to depend on pipeline data, patent timelines, drug pricing policy and interest rates, which influence how investors value future earnings. For now, the session illustrates how relative safety can become its own catalyst when sentiment elsewhere sours.